speb/financial-data huggingface dataset:
BIOA cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: 124315000.00
BIOA income_statement (quarterly, 2026-03-31) — Net Income: -22253000.00
BIOA income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -22253000.00
BIOA income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -22253000.00
BIOA income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -22253000.00
BIOA income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -22253000.00
BIOA cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -22253000.00
BIOA income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -22253000.00
BIOA income_statement (quarterly, 2026-03-31) — Net Interest Income: 3229000.00
BIOA cash_flow (quarterly, 2026-03-31) — Net Investment Purchase And Sale: -46727000.00
BIOA cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: -1500000.00
BIOA cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: -1500000.00
BIOA income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: 3229000.00
BIOA cash_flow (quarterly, 2026-03-31) — Net Other Financing Charges: -807000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Net PPE: 3799000.00
BIOA cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: -26000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 379121000.00
BIOA income_statement (quarterly, 2026-03-31) — Normalized EBITDA: -22044000.00
BIOA income_statement (quarterly, 2026-03-31) — Normalized Income: -22146000.00
BIOA cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: -24046000.00
BIOA cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: 107000.00
BIOA income_statement (quarterly, 2026-03-31) — Operating Income: -25375000.00
BIOA income_statement (quarterly, 2026-03-31) — Operating Revenue: 2772000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 44386785.00
BIOA balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 7957000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Other Current Borrowings: 1159000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 714000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Other Equity Adjustments: 73000.00
BIOA income_statement (quarterly, 2026-03-31) — Other Gand A: 7737000.00
BIOA income_statement (quarterly, 2026-03-31) — Other Income Expense: -107000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Other Investments: 100000.00
BIOA cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: -225000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 215000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Other Properties: 3796000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 141417000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Payables: 3066000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 7117000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Preferred Stock: 0.00
BIOA income_statement (quarterly, 2026-03-31) — Pretax Income: -22253000.00
BIOA cash_flow (quarterly, 2026-03-31) — Proceeds From Stock Option Exercised: 1707000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
BIOA cash_flow (quarterly, 2026-03-31) — Purchase Of Investment: -80214000.00
BIOA cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: -26000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Receivables: 709000.00
BIOA income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 63000.00
BIOA cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -1500000.00
BIOA income_statement (quarterly, 2026-03-31) — Research And Development: 20410000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -355669000.00
BIOA cash_flow (quarterly, 2026-03-31) — Sale Of Investment: 33487000.00
BIOA income_statement (quarterly, 2026-03-31) — Selling General And Administration: 7737000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Share Issued: 44386785.00
BIOA cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 4256000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 379121000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 379121000.00
BIOA income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
BIOA income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.00
BIOA balance_sheet (quarterly, 2026-03-31) — Total Assets: 397654000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 379121000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Total Debt: 4034000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 379121000.00
BIOA income_statement (quarterly, 2026-03-31) — Total Expenses: 28147000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 18533000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 5794000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 2706000.00
BIOA income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: -25375000.00
BIOA income_statement (quarterly, 2026-03-31) — Total Unusual Items: -107000.00
BIOA income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -107000.00
BIOA balance_sheet (quarterly, 2026-03-31) — Working Capital: 376033000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Accumulated Depreciation: -42850000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Additional Paid In Capital: 3847000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Allowance For Doubtful Accounts Receivable: -363000000.00
BIOCON.NS income_statement (annual, 2022-03-31) — Amortization: 1310000000.00
BIOCON.NS cash_flow (annual, 2022-03-31) — Amortization Cash Flow: 1310000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Assets Held For Sale Current: 0.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Buildings And Improvements: 22467000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Cash Equivalents: 300000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Cash Financial: 6326000000.00
BIOCON.NS cash_flow (annual, 2022-03-31) — Common Stock Dividend Paid: 0.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Dividends Payable: 4000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 145000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Finished Goods: 3801000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Fixed Assets Revaluation Reserve: 9000000.00
BIOCON.NS cash_flow (annual, 2022-03-31) — Gain Loss On Sale Of Business: -299000000.00
BIOCON.NS income_statement (annual, 2022-03-31) — General And Administrative Expense: 1869000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Gross Accounts Receivable: 20945000000.00
BIOCON.NS income_statement (annual, 2022-03-31) — Interest Income: 1121000000.00
BIOCON.NS income_statement (annual, 2022-03-31) — Interest Income Non Operating: 1121000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Land And Improvements: 3179000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Long Term Equity Investment: 80000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Machinery Furniture Equipment: 73119000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Non Current Deferred Revenue: 12151000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Non Current Prepaid Assets: 1033000000.00
BIOCON.NS cash_flow (annual, 2022-03-31) — Other Cash Adjustment Outside Changein Cash: 338000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Other Investments: 2629000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Other Payable: 3626000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Other Receivables: 14836000000.00
BIOCON.NS income_statement (annual, 2022-03-31) — Other Special Charges: 835000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Prepaid Assets: 4207000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Properties: 0.00
BIOCON.NS cash_flow (annual, 2022-03-31) — Purchase Of Business: 0.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Raw Materials: 8557000000.00
BIOCON.NS income_statement (annual, 2022-03-31) — Rent And Landing Fees: 38000000.00
BIOCON.NS income_statement (annual, 2022-03-31) — Rent Expense Supplemental: 38000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Restricted Cash: 7000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Retained Earnings: 68273000000.00
BIOCON.NS income_statement (annual, 2022-03-31) — Selling And Marketing Expense: 2438000000.00
BIOCON.NS income_statement (annual, 2022-03-31) — Selling General And Administration: 4307000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Treasury Shares Number: 7520315.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Treasury Stock: 324000000.00
BIOCON.NS balance_sheet (annual, 2022-03-31) — Work In Process: 10624000000.00
BIOCON.NS income_statement (annual, 2022-03-31) — Write Off: 8000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — +Operating Expense: 56402000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — +Total Revenue: 109341000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Accounts Payable: 38420000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Accounts Receivable: 35732000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -51172000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 4390000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Allowance For Doubtful Accounts Receivable: -617000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Amortization: 2914000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Amortization Cash Flow: 2914000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Available For Sale Securities: 1957000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Basic Average Shares: 1193095945.00
BIOCON.NS income_statement (annual, 2023-03-31) — Basic EPS: 3.88
BIOCON.NS cash_flow (annual, 2023-03-31) — Beginning Cash Position: 6537000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Buildings And Improvements: 25849000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Capital Expenditure: -17263000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Capital Lease Obligations: 2481000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Capital Stock: 6003000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 13232000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Short Term Investments: 37260000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Cash Dividends Paid: -718000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Cash Equivalents: 360000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Cash Financial: 12872000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Change In Inventory: 8862000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Change In Other Current Assets: 7582000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Change In Payable: -37359000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Change In Receivables: 15905000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Change In Working Capital: -5010000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Changes In Cash: 6194000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Common Stock: 6003000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Common Stock Dividend Paid: -718000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Common Stock Equity: 178669000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Common Stock Issuance: 12663000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Common Stock Payments: -647000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Construction In Progress: 25875000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Cost Of Revenue: 36668000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Current Assets: 123340000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Current Capital Lease Obligation: 390000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Current Debt: 24802000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 25192000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Current Liabilities: 85107000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Current Provisions: 1486000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Deferred Tax: 2541000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Depreciation: 8217000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 11131000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 11131000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Depreciation Income Statement: 8217000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Derivative Product Liabilities: 14297000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Diluted Average Shares: 1195925590.00
BIOCON.NS income_statement (annual, 2023-03-31) — Diluted EPS: 3.87
BIOCON.NS income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: 4627000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Dividends Payable: 4000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — EBIT: 13161000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — EBITDA: 24292000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Effect Of Exchange Rate Changes: 217000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — End Cash Position: 12948000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Financial Assets: 1454000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 545000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Financing Cash Flow: 130487000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Finished Goods: 15996000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Fixed Assets Revaluation Reserve: 9000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Free Cash Flow: 1262000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Gain Loss On Investment Securities: -416000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of Business: -1562000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of PPE: 52000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — General And Administrative Expense: 2651000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Goodwill: 161362000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Goodwill And Other Intangible Assets: 266621000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Gross Accounts Receivable: 36349000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Gross PPE: 152398000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Gross Profit: 72673000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Hedging Assets Current: 704000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Held To Maturity Securities: 5380000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Interest Expense: 4190000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 4190000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Interest Income: 1124000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 1124000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Interest Paid Cff: -4856000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Interest Received Cfi: 1233000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Inventory: 42437000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 356376000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: -142818000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 7882000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Issuance Of Capital Stock: 12663000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Issuance Of Debt: 109399000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Land And Improvements: 3292000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Long Term Capital Lease Obligation: 2091000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Long Term Debt: 152905000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 154996000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Long Term Debt Issuance: 109399000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Long Term Debt Payments: -281000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Long Term Equity Investment: 1378000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Long Term Provisions: 2265000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 93472000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Minority Interest: 46219000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Minority Interests: -1803000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Net Business Purchase And Sale: -122171000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Net Common Stock Issuance: 12016000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Net Debt: 164475000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Net Foreign Currency Exchange Gain Loss: 971000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Net Income: 4627000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: 4627000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: 6430000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: 4627000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: 4627000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 6430000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: 6430000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Net Intangibles Purchase And Sale: -1303000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Net Interest Income: -3066000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: -4648000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: 124159000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: 109118000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: -3066000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Net PPE: 101226000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: -15929000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Net Short Term Debt Issuance: 15041000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: -87952000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Revenue: 2901000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Assets: 3010000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Liabilities: 3818000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 2869000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: 25290000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Normalized Income: 5475300000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: 18525000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Operating Income: 16271000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Operating Revenue: 109341000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 1193987732.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 5880000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Other Current Liabilities: 2348000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Other Equity Interest: 2740000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Other Intangible Assets: 105259000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Other Inventories: 3767000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Other Investments: 5380000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: 3564000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Other Non Current Assets: 1000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Other Non Current Liabilities: 25573000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 39000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 15917000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Other Payable: 4061000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Other Properties: 3910000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Other Receivables: 1321000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 24028000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Other Special Charges: 796000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Payables: 48171000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 5880000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Pretax Income: 8971000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Provisionand Write Offof Assets: 54000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Purchase Of Business: -156645000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Purchase Of Intangibles: -1303000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Purchase Of Investment: -187143000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Purchase Of PPE: -15960000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 8962000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 36668000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 11131000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 29000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 29000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Repayment Of Debt: -281000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Repurchase Of Capital Stock: -647000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Research And Development: 4898000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 6000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: 160859000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Sale Of Business: 34474000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Sale Of Investment: 182495000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 31000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 2216000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 4867000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Share Issued: 1200600000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Special Income Charges: -806000000.00
BIOCON.NS cash_flow (annual, 2023-03-31) — Stock Based Compensation: 1376000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 178669000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: -87952000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: -149700000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Tax Provision: 2541000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.15
BIOCON.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -2286000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Total Assets: 520428000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 331574000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Total Debt: 180188000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 224888000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Total Expenses: 93070000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 295540000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 397088000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 210433000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 5686000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Total Unusual Items: -998000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: -998000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Tradeand Other Payables Non Current: 6583000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Treasury Shares Number: 6612268.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Treasury Stock: 971000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Work In Process: 13712000000.00
BIOCON.NS balance_sheet (annual, 2023-03-31) — Working Capital: 38233000000.00
BIOCON.NS income_statement (annual, 2023-03-31) — Write Off: 10000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — +Operating Expense: 78547000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — +Total Revenue: 141958000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 62720000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 62306000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -59151000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 4940000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -646000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Amortization: 6295000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 6295000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 7000000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 1195428813.00
BIOCON.NS income_statement (annual, 2024-03-31) — Basic EPS: 8.55
BIOCON.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 12999000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 31555000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -19316000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 5471000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 6003000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 12334000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 31118000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -2030000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Cash Equivalents: 698000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 11636000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Change In Inventory: -8864000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: -2679000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Change In Payable: 29365000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Change In Receivables: -24174000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: -6352000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Changes In Cash: -3833000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Common Stock: 6003000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Common Stock Dividend Paid: -2030000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 197837000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Common Stock Issuance: 307000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Common Stock Payments: 0.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 42156000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 49066000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Current Assets: 151792000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 547000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Current Debt: 27972000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 28519000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 153588000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 1795000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Deferred Tax: 2274000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Depreciation: 9393000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 15688000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 15688000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 9393000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Derivative Product Liabilities: 3299000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 1196870502.00
BIOCON.NS income_statement (annual, 2024-03-31) — Diluted EPS: 8.54
BIOCON.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 10225000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 6000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Dividends Received Cfi: 0.00
BIOCON.NS income_statement (annual, 2024-03-31) — EBIT: 24996000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — EBITDA: 40684000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Effect Of Exchange Rate Changes: 29000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — End Cash Position: 9195000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Financial Assets: 2657000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 542000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: -23327000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 24129000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Fixed Assets Revaluation Reserve: 9000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: 10223000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: -1701000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of Business: -5307000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: 12000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 5894000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Goodwill: 163724000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 266591000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 62952000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 181233000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Gross Profit: 92892000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Hedging Assets Current: 1384000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Held To Maturity Securities: 4000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Interest Expense: 9744000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 9744000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Interest Income: 1613000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 1613000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -8474000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 1446000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Inventory: 49439000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 355133000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -10045000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 7542000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Issuance Of Capital Stock: 307000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Issuance Of Debt: 13718000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 3747000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 4924000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 129324000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 134248000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Long Term Debt Issuance: 13718000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Long Term Debt Payments: -27678000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Long Term Equity Investment: 0.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 2376000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 99461000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Minority Interest: 54911000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Minority Interests: -2753000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Net Business Purchase And Sale: -5532000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Net Common Stock Issuance: 307000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Net Debt: 144962000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: -1054000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Net Income: 10225000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 10225000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 12978000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 10225000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 10225000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 12978000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 12978000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Net Intangibles Purchase And Sale: -2511000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Net Interest Income: -8131000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: 13124000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: -12712000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: -13960000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: -8131000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Net PPE: 122082000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -16572000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: 1248000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: -68754000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Revenue: 3107000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Assets: 3173000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 3915000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 1886000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 30315000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Normalized Income: 1411350000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 29539000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Operating Income: 14345000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Operating Revenue: 141958000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 1196804982.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 7151000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 27779000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 3201000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 102867000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Other Inventories: 2798000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: 14247000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 4280000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Other Non Current Liabilities: 3107000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 34000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 22128000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Other Payable: 7857000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Other Properties: 4314000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 389000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 18784000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Other Special Charges: -8679000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Payables: 74423000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 7151000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Pretax Income: 15252000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: -182000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Purchase Of Business: -5532000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Purchase Of Intangibles: -2511000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: -53340000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -16805000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 8366000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 49066000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 15688000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 3000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 3000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Repayment Of Debt: -27678000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Repurchase Of Capital Stock: 0.00
BIOCON.NS income_statement (annual, 2024-03-31) — Research And Development: 7123000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 5000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 176028000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Sale Of Business: 0.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Sale Of Investment: 66464000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 233000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 2966000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 8860000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Share Issued: 1200600000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Special Income Charges: 8668000000.00
BIOCON.NS cash_flow (annual, 2024-03-31) — Stock Based Compensation: 1006000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 197837000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: -68754000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: 1555350000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Tax Provision: 2274000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.15
BIOCON.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -2923000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Total Assets: 560707000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 327161000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Total Debt: 162767000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 252748000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Total Expenses: 127613000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 307959000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 408915000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 154371000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 3840000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Total Unusual Items: 10369000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: 10369000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Tradeand Other Payables Non Current: 7426000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Treasury Shares Number: 3795018.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Treasury Stock: 971000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Work In Process: 14146000000.00
BIOCON.NS balance_sheet (annual, 2024-03-31) — Working Capital: -1796000000.00
BIOCON.NS income_statement (annual, 2024-03-31) — Write Off: 11000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 63689000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 61292000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 14312000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 6210000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 6003000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 16877000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 31172000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 6003000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 209932000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 43542000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 151535000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 1012000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 41683000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 42695000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 158051000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 2076000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Derivative Product Liabilities: 189000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Financial Assets: 1709000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Goodwill: 164673000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 266924000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 124534000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Hedging Assets Current: 1379000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 49651000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 371430000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 14312000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 5198000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt: 119815000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 125013000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 2260000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Minority Interest: 57268000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Net Debt: 144621000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 124534000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: -56992000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Assets: 2214000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 3907000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 1197654456.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 8041000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 4742000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 203929000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Other Intangible Assets: 102251000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 5474000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Liabilities: 3084000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 80992000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 14295000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Payables: 66370000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 1200600000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 209932000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: -56992000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 571279000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 329747000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 167708000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 267200000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 304079000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 419744000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 146028000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 2681000000.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Treasury Shares Number: 2945544.00
BIOCON.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: -6516000000.00
BIOCON.NS income_statement (quarterly, 2024-12-31) — Gross Profit: 24621000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — +Operating Expense: 82283000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 22433000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — +Total Revenue: 150522000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 43581000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 65487000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 65487000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 54879000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 54879000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -67962000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -67962000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 5182000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 5182000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -627000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -627000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Amortization: 6859000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Amortization Cash Flow: 6859000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 6910000000.00